Upgrade to SI Premium - Free Trial

Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald After Ph 2 CADENCE Data Release

March 30, 2026 9:32 AM
Cantor Fitzgerald analyst Carter Gould reiterated a Neutral rating and $120.00 price target on Merck (NYSE: MRK).The analyst commented, "Merck ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments